

## Curriculum Vitae

Cand.med. januar 89.

Ret til selvstændigt virke som læge, april 1994.

Dr. Med. december 1997.

### ANSÆTTELSE:

Scholarstipendiat, Fysiologisk Institut, Aarhus Universitet (AU) (1.8.86-31.12.86; 1.6.87-31.7.87; 1.1.88-31.6.88)

Kandidatstipendiat, Fysiologisk Institut, AU (1.2.89 - 31.12.91), Institut for Medicinsk Biokemi (IMB), AU (1.1 1992 - 31.9 1992)

Reservelæge, Nyremedicinsk afdeling C, Skejby sygehus (1.10.92- 31.9.93), Ortopædkirurgisk afd. E, Århus Amtssygehus (1.10.93 - 31.3.94)

Forskningsadjunkt, IMB, AU (1.4.94-28.02.96)

Lektorvikar, IMB, AU (1.3.96-28.02.97)

Forskningsadjunkt, IMB, AU (1.3.97-31.4.98)

Visiting Scientist, European Molecular Biology Laboratory, Heidelberg, Tyskland (1.8.97-31.5.98).

Lektor, IMB, AU (1.5.98-31.9.04)

Instituttleder, IMB, AU, (1.2.01-)

Professor, IMB (1.10.04-)

Publiceret 70 original artikler og 11 oversigtsartikler

Leder det Neurodegenerative forskningslaboratorie på IMB (<http://www.neurodegeneration.au.dk>) som fokuserer på molekylære mekanismer ved parkinsonistiske sygdomme og demens. Gruppen omfatter aktuelt 1 professor, 1 post doc., 4 Ph.D. studerende, 1 prægraduate specialestuderende og 2 laboranter og har hidtil gradueret 5 PhD kandidater og 8 specialestuderende.

**Forskningsformidling:** Publiceret 70 originalarbejder og 11 oversigtsartikler. Priser; Guldmedalje for prisopgave ved AU 1986. Dr. Med. 1997 ved AU på afhandlingen "Structure and Function of Plasminogen Activator Inhibitor-2. An intracellular serine proteinase inhibitor modulating apoptosis"; Alzheimer prisen 2010 fra Dansk Alzheimer Forening.

Etablerede i 1994 forskningslaboratoriet for Molekylær Neurodegenerativ forskning med interesse for Parkinson sygdom og demens. Gruppen har udnyttet den store viden opnået gennem klinisk genetiske patientstudier og det humane genomprojekt til at fokusere på nøgle molekyler i de neurodegenerative processer. Specielt arbejdet med proteinet  $\alpha$ -synuclein har ført til at vi har opnået en prominent rolle i den molekylære Parkinson forskning. Det har bl.a. ført til invitation som rådgiver ved Michael J Fox Fondens  $\alpha$ -synuclein summit Jan. 2010 og Synuclein Imaging Workshop Nov. 2010 og som medorganisator af årlige workshops om  $\alpha$ -synuclein siden 2007 i Adelaide, 2008 i Lausanne, 2009 Beijing og 2010 San Diego og i 2011 på Naxos i Grækenland. Desuden deltaget ved talrige videnskabelige møder og kongresser, heraf oftest som invited speaker, flere gange som chairman, organisator af symposier bl.a. i 2009 Alfred Benzon symposiet, Functional and Pathogenic Protein Aggregation. Forelæst på Lundbeck A/S, Neurosearch A/S, NsGene A/S, Novo A/S, Boehringer Ingelheim GmbH, Elan. Afholdt seminarer ved universiteter i Norge, Sverige, Svejs, Frankrig, Tyskland, England, USA, Japan, Kina, Australien. Indleveret 3 patentansøgninger. Bestyrelsesmedlem ved Arne Hansens legat (2005-2008) samt Dansk Neuroforskningssenter, som er et initiativ mellem Århus Universitetshospital og Aarhus Universitet. **Bedømmelser:** Adjunkt og lektoransøgere ved Fysiologisk Institut, AU; Biomedicin, Aalborg Universitet. Tenure track ansøgning ved Cornell University, New York og EPFL, Lausanne. Forfremmelser ved Flinders University, Adelaide og Prince of Wales Medical Research Centre, Sydney. Expertbedømmer for the European research Council; Norges Forskningsråd, Israel Science Foundation, Council for Chemical Sciences of the Netherlands Organisation for Scientific Research, de britiske fonde The Parkinson's disease Society, The Wellcome Trust, The Cunningham Trust, Telethon Fondazione Onlus og Estonian Science Foundation.

Ph.D. afhandlinger ved de Læge- og Naturvidenskabelige fakulteter, AU og Københavns Universitet samt Hobart University. Censor for speciale og del A examener ved det Naturvidenskabelige Fakultet, AU, Syddansk Universitet (SDU) samt Ålborg Universitet.

Referee for tidsskrifterne The Lancet, J. Neuroscience, Neurology, J. Biol. Chem., J. Mol. Biol., J. Mol. Genetics., Eur. J. Neuroscience, Biochemical J., Biochim. Biophys. Acta, FEBS Lett., FASEB Journal, Brain Research, J. Neurochemistry, Experimental Neurology, Molecular Neurodegeneration, Neuroscience Lett., Journal of Alzheimer's disease, Trends in Neuroscience and Immunol. Methods.

**Undervisning:** som forelæser om neurodegeneration ved lægeuddannelsen på AU, på A-kurset for speciallægeuddannelsen af neurologer samt ved præ- og postgraduate kurser for stud. scient'er i AU, Syddansk Universitet og Danmarks Farmaceutiske Højskole. Underviser og koorganisator af FP7 Neurasync PhD workshop "Effect of protein misfolding on neuronal cell homeostasis", Athens.

Vejledt Ph.D. studerende på AU, SDU, Dansk Jordbrugsforskning i Foulum, Farmaceutisk højskole, Lundbeck A/S og ingeniørstuderende ved Ålborg Universitet, samt post doc, ph.d., speciale- og udvekslingsstuderende i mit eget laboratorium.

**Forskningsledelse:** Leder det Neurodegenerative forskningslaboratorie på IMB (<http://www.neurodegeneration.au.dk>) som fokuserer på molekylære mekanismer ved parkinsonistiske sygdomme og demens. Gruppen omfatter aktuelt 1 professor, 1 post doc., 4 Ph.D. studerende, 1 prægraduate specialestuderende og 2 laboranter og har hidtil gradueret 5 PhD kandidater og 8 specialestuderende. Gruppen deltager i en række nationale og internationale forskningssamarbejder omkring udvikling af nye sygdomsmodeller, identifikation af nye sygdomsmarkører samt udvikling af nye reagenser – alle med det mål at udvikle behandlingsformer som kan stoppe eller hæmme udviklingen af Parkinson's sygdom og demens.

Samarbejderne omfatter flere initiativer støttet af Michael J Fox fonden, Nordisk Center of Excellence in Molekylær Neurodegenerativ Forskning, innovationskonsortiet CureND, det EU støttede integrerede træningsnetværk Neurasync og gruppen har modtaget afgørende og vedholdende støtte fra bl.a. Lundbeckfonden.

### **Forskningsnetværk**

Nordic Centre of Excellence in Molecular Neurodegeneration

Innovations konsortium CureND

FP7 Neurasync integrated training network

FP7 MEFOPA

### **ORGANISATORISK ERFARING**

Medlem af Aarhus Universitets Råd af Yngre Læger 1.12.91-31.09.92. Medlem af undervisningsudvalget på IMB 08.08.99-31.1.01. Leder af *ad hoc* udvalget på IMB, der forestod indretning af øvelseslaboratorier for IMB i bygn 180 fra juni 2000 til foråret 2001. Institutleder på IMB fra Februar 2001 med diverse administrative opgaver herunder deltagelse i sikkerhedsudvalget og formand for Bestyrelsen, Samarbejdsudvalget. Medlem af Fakultetssamarbejdsudvalget ved det Sundhedsvidenskabelige Fakultet, AU 2001-  
Kursus for Institutledere. 5 moduler over 13 dage i 2002-2003 arrangeret i samarbejde mellem Rektorkollegiet og Syddansk Universitets Efteruddannelse.

### **VIDENSKABELIGE FORENINGER**

Medlem af Biokemisk Forening, Dansk Selskab for Neurovidenskab, Society for Neuroscience, European Society for Neurochemistry, International Society for Neurochemistry, American Society for Biochemistry and Molecular Biology. Danmarks Naturvidenskabelige Akademi.

### **Advisory work**

**Michael J Fox Foundation January 2011** – Teleconf. on bioimaging of  $\alpha$ -synuclein pathology in brain

### **FOREDRAG/ MØDER/WORKSHOPS:**

- " $\alpha_2$ M/PZP receptors in the human placenta", Workshop on Chemistry and Biology of  $\alpha_2$ -macroglobulin and Related Plasma Proteins, Aarhus Universitet, nov. 86. *Oral presentation*
- 2. "Placenta has receptors for pregnancy zone protein-proteinase complexes". Scand. Physiological Society, møde København, nov. 86. *Oral presentation*
- $\alpha_2$ -Macroglobulin and related plasma proteins. Structure, Function, Regulation. Conference, Aachen, Tyskland, Okt. 1990.
- 20th Linderstrøm-Lang conference. The role of protein structure in biological regulation. Vingsted, Maj 1991.
- 5. "Cell- and ligand specific receptor-binding and endocytosis of u-PA and u-PA/inhibitor complexes in human blood cells and trophoblastic cell lines", The third international workshop on the molecular and cellular biology of plasminogen activation, Helsingør, maj 1991. *Oral presentation*
- International Falk symposium on hepatic endocytosis, Hamburg, Tyskland, Juni 1991.
- 7. "Transglutaminase catalysed crosslinking of PAI-2" hos Associate professor E. K. O. Kruithof. Hematology-Oncology Laboratory, University Hospital Center, Lausanne, Svejt Nov. 1991. *Oral presentation*
- "PAI-2 and its putative role in apoptosis" hos Professor S. O. Døskeland. Department of Cell Biology, Universitet i Bergen, Norge, Juni 1992. *Oral presentation*
- Eleventh International Congress on Fibrinolysis, København, Juni 1992.
- 10. "The type-2 inhibitor of plasminogen activator (PAI-2) is a substrate for activated factor XIII and for tissue transglutaminase. Cross-linking to matrix and membrane structures", Eleventh International Congress on Fibrinolysis, København, juni 1992. *Oral presentation*
- 11. "Apoptosis associated cleavage of PAI-2" og "The exon 3 encoded segment in PAI-2, a mediator of covalent and reversible interactions" hos Associate professor E. Remold-O'Donnell, The Center for Blood Research, Inc. Boston, USA, henholdsvis Sept. 1993 og Maj 1995. *Oral presentations*
- 12. 4th International Workshop on the Molecular and Cellular Biology of Plasminogen Activation, Cold Spring Harbor, USA, Sept. 28 - Oct. 3, 1993.
- 13. "Gln<sup>83, 84, 86</sup> in an interhelical insertion of plasminogen activator inhibitor-2 are essential for transglutaminase-catalyzed cross-linking." Fourth International Conference on Transglutaminases and Protein crosslinking reactions. Debrecen, Ungarn, Aug. 1994. *Invited speaker*.

14. "Cleaved intracellular plasminogen activator inhibitor-2 in human myeloleukemia is a marker of apoptosis" Second Euroconference on Apoptosis, Kinsale, Ireland, Oct. 1994. *Poster*
15. "The exon 3 encoded segment in PAI-2, a mediator of covalent and reversible interactions" hos Professor R. Carrell, Dept. of Haematology, MCR Centre, Cambridge, UK, Maj 1995. *Oral presentation*
16. "Residues in the synuclein consensus motif of the a-synuclein fragment, NAC, participates in transglutaminase-catalyzed cross-linking to Alzheimer amyloid Ab peptide" Neurodegenerative Diseases '95: Molecular and Cellular Mechanisms, and Therapeutic Advances, Washington DC, USA, May 1995. *Poster*
17. "The exon 3 encoded segment in PAI-2, a mediator of covalent and reversible interactions" hos Dr. B. Pepinsky, Biogen, Cambridge, USA, Maj 1995. *Oral presentation*
18. Neurodegenerative Diseases '95: Molecular and Cellular Mechanisms, and Therapeutic Advances, Washington DC, USA, May 1995.
19. "Intracellular binding and apoptosis-associated modification of PAI-2. Importance of the unique exon 2 encoded sequence" 5th International Workshop on Molecular and Cellular Biology of Plasminogen Activation, Hämeenlinna, Finland, August 1995. *Poster*
20. "Ab binding to a-synuclein" hos Dr. B. Hyman, Mass General Hospital, Boston, USA, April 1996. *Oral presentation*
21. International Symposium on the Chemistry and Biology of SERPINS. The University of North Carolina at Chapel Hill, April. 1996.
22. Molecular Mechanisms in Alzheimers Disease, Keystone Symposia, Colorado , Februar, 1997
23. "a-synucleins interaction with pathogenic ligands, Ab and tau" og "Axonal transport of a-synuclein" hos Dr. C.Dotti, EMBL, Heidelberg, Tyskland, Februar 1997 and Maj 1998. *Oral presentations*
24. "Axonal transport of a-synuclein" hos Prof. A. Dahlström, Anatomisk Institut, Göteborg Universitet, Oktober 1998. *Oral presentation*
25. Fatal Attraction within neurons: intracytoplasmic protein aggregates in Alzheimers disease and related neurodegenerative diseases, Fondation Ipsen, Paris, April, 1999
26. XIII International Congress on Parkinson's Disease, Vancouver, July, 1999.
27. Joint meeting of the International and the European Society for Neurochemistry, Berlin, August, 1999.
28. Neurodegenerative diseases: loss of function through gain of function, Fondation Ipsen, Paris, Febr, 2000
29. "a-synuclein - structural and functional aspects of axonal transport and ligand interactions" Neuropathology and genetics of dementia, XVIII International winter meeting of the Swiss Society of Neuropathology, March, 2000, *invited speaker*.
30. "a-synuclein in Parkinson's disease" hos Lundbeck A/S, Valby, Maj 2000. *Oral presentation*
31. "Molekylære og cellulære mekanismer ved dopaminerg nervecelledød i Parkinsons sygdom" Danish Movement Disorder Society, General assembly, Aarhus, May, 2000, *invited speaker* for Professor Henning Pakkenberg-forelæsningsen 2000
32. Sixth International Congress of Parkinson's disease and Movement Disorders, Barcelona, Juni, 2000
33. "a-synuclein and parkin in Parkinson's disease" hos Dr. W. P. Gai, Flinders Med. Ctr., Adelaide, Australien, Aug. 2000. *Oral presentation*
34. "a-synuclein and parkin in Parkinson's disease" hos Prof. C. Masters, Dept. Pathology, University of Melbourne, Aug. 2000. *Oral presentation*
35. "a-synuclein, Lewy legemer, parkin, ligand interaktioner og mulige patogene mekanismer ved dopaminerg celledød", Arbejdsseminar om patofysiologiske/genetiske aspekter ved parkinsonisme, John F. Kennedy Institut, Copenhagen, Nov. 2000, *invited speaker*.
36. "a-synuclein and parkin and their involvement in Parkinson's disease", Molecular Mechanisms of Neuronal Stress and Degeneration, Joint meeting of Danish Society of Neuroscience and Danish Society of Biochemistry and Molecular Biology, Copenhagen, Nov, 2000, *invited speaker*.
37. Therapeutic opportunities in neurodegenerative diseases, Cold Spring Harbor Laboratory, USA. Nov. 2000
38. "Lessons from heritable Parkinson's disease: Opposing roles for a-synuclein and parkin." Hos Fysiologisk Institut, Aarhus Universitet, Februar 2001. *Oral presentation*
39. "a-synuclein and parkin: Molecular actors in Parkinson's disease", Neurodegeneration: Mechanisms, models and markers, Dansk Selskab for Neurovidenskab, Sandbjerg, Danmark, Maj 2001, *Invited speaker*.
40. "Cellular stress and apoptotic signals leads to caspase-mediated parkin cleavage", Proteolysis in Biological Control, Cold Spring Harbor Laboratory, Maj 2001. *Oral presentation*
41. Neurodegeneration: Mechanisms, models and markers, Dansk Selskab for Neurovidenskab, Sandbjerg, Danmark, Maj 2001
42. "Alpha-synuclein aggregation - causes and effects" " 8<sup>th</sup> CCGH symposium "New Paradigms of Molecular Chaperones in the Post Genomic Era" Japan, July 2001, *invited speaker and session chairman*.
43. "Apoptosis associated cleavage of Parkin and novel studies on alpha-synuclein filament binding proteins" Hos Prof. Y. Mizuno, Juntendo medical School, Tokyo, Juli 2001. *Oral presentation*
44. "Molecular studies in a-synuclein and parkin - key players in Parkinson's disease" Medicon Valley BioConference 2001", 19 September 2001, Copenhagen, Denmark, *Invited speaker*.
45. "a-synuclein and Parkin, molecular players in Parkinson's disease" Institut for Molekylær og Strukturel Biologi, Aarhus Universitet, Oktober, 2001. *Oral presentation*
46. "Molecular biology of a-synuclein and parkin, key players in Parkinson's disease" International Workshop on neurodegeneration: Future Molecular and Clinical Research in Parkinsonisms. Beijing, Kina, Oktober, 2001, *Invited speaker and session chairman*.
47. "Molecular studies in alpha-synuclein and parkin - key players in Parkinson's disease" hos prof. Gong Ju, The Fourth Military Medical University, Xi'an, Kina, Oct 18, 2001. *This and the following three seminars were held as part of an*

*International Neuroscience Delegation.*

48. "Molecular studies in alpha-synuclein and parkin – key players in Parkinson's disease" hos prof. Xuegang Luo, Dept. Anatomy and neurobiology, Xiangya Medical College, Central South University, Changsha, Kina, Oct 22, 2001. *Oral presentation*
49. "Molecular studies in alpha-synuclein and parkin – key players in Parkinson's disease" hos prof. Feng Zhongtang, Kunming Medical College, Kunming, Yunnan, Kina, Oct 26, 2001. *Oral presentation*
50. "Molecular studies in alpha-synuclein and parkin – key players in Parkinson's disease" hos prof. Cheng Zhang, Dept. Of Neurology, First Affiliated Hospital, Sun Yat-Sen University of Medical Sciences, Kina, Oct 30, 2001 *Oral presentation*
51. "Studies of monomeric and filamentous a-synuclein. Lessons for Parkinson's disease ?", Prof. Anders Björklund, Wallenberg Neuroscience Center, Lund University, Sweden, Nov. 2001 *Oral presentation*
52. "Den molekylær-patologiske baggrund for Parkinson's sygdom" Molekylær medicinsk seminar ved den Molekylær Medicinske Forskningsenhed ved Århus Universitetshospital, vært prof. Niels Gregersen, febr. 2002 *Oral presentation*
53. "Posttranslational modifications of keyplayers in Parkinson's disease" FEBS Biochemistry congress, Istanbul Oct, 2002, *invited speaker*
54. Neuroscience 2002, SfN's 32<sup>nd</sup> Annual Meeting, Orlando, USA, Nov. 2002,
55. "Misfolded proteins and cellular responses in Parkinson's disease" 1. Internatinal Workshop "Frontiers in Molecular Neuropathology" RIKEN Brain Science Institute, Tokyo, Japan, November 2002, *invited speaker and session chair*
56. "Aggregated a-synuclein species inhibit proteasomal function. A general mechanism whereby amyloid aggregates causes polyubiquitination in neurodegenerative diseases" Neuroregeneration and degeneration. New targets in prevention of neurodegeneration meeting organised by the Danish Society for Neuroscience. Copenhagen. March 2003. *Invited speaker.*
57. "Mechanisms active in degeneration of dopaminergic neurons, with focus on alpha-synuclein and parkin" 3<sup>rd</sup> German-Scandinavian meeting on Movement Disorders, Göteborg/Kiel, maj 2003, *Invited speaker*
58. "Proteasomal inhibition by a-synuclein filaments and oligomers and attenuation by HSP-70. A general mechanism for neurodegenerative diseases with cytoplasmic protein aggregates". SFB symposium on Molecular Mechanisms of Neurodegeneration, Wildbad Kreuth, Germany, July, 2003. *Invited speaker*
59. "Misfolded proteins and cellular responses in Parkinson's disease" 32<sup>nd</sup> Annual meeting of the Danish Society for Biochemistry and Molecular Biology on Molecular Biology of Human diseases, Gl. Avernæs, Danmark, Oct 2003. *Invited speaker.*
60. "Proteasomal inhibition by asy filaments and oligomers and reversal by endogenous proteins" Growth and death in the nervous system. Int. Winter meeting St. Moritz. Marts 2004. *Invited speaker.*
61. "Alpha-synucleins relation to aggregation" Gordon Research Conference on Macromolecular organization and Cell function, Oxford, UK, Aug. 2004. *Invited speaker.*
62. "Up- and down stream of a-synuclein aggregation. Neuroscience. San Diego, Okt. 2004. *Speaker.*
63. a-synuclein and neurodegenerative diseases. Missing biological and biophysical links. Laboratoire Léon Brillouin, CEA, Saclay, Frankrig. Marts 2005. *Invited speaker.*
- "The gain of function upon a-synuclein aggregation" First international Institute for Complex Adaptive Matter (I2CAM) Exploratory Workshop on protein aggregation and amyloid formation in systemic and neurodegenerative disease: Physical, Molecular and Biological Approaches, Lausanne, Switzerland. July 2005. *Invited speaker.*
64. "Ligand stimulated protein polymerization and aggregation in synucleinopathies" Beijing International Symposium on Neurodegenerative diseases and Stroke. Beijing, China. September 2005. *Invited speaker and chairman.*
65. "Biology of a-synuclein aggregation" Federation of European neuroscience Societies (FENS) winter school. Kitzbühel., Austria. December 2005. *Invited speaker.*
66. "Pathogenic mechanisms in a-synucleinopathies" Dementia, Ageing and Neurodegenerative Diseases group (DANDIS) Satellite meeting, Sydney, Australia, January 2006. *Invited speaker.*
67. EMBO-FEBS workshop on amyloid formation. Florence, Italy, March 2006.
68. "p25a in a-synucleinopathies" Australian Neuroscience Society Annual meeting, Sydney, Australia, February 2006. *Invited speaker.*
69. 33) "Alpha-synucleinopathies – mechanisms of aggregation and neurodegeneration" *Invited speaker and chairman. Organiser of the symposium "Alpha-synucleinopathies – mechanisms of aggregation and neurodegeneration" 7<sup>th</sup> Biennial Meeting of the Asian Pacific Society for Neurochemistry, Singapore, July 2006.*
70. Cell Death. Gordon Research Conference. Big Sky Resort, Montana, USA, September 2006.
71. "Udvikling af eksperimentelle neuroprotektive behandlingsformer". Jydsk Medicinsk Selskab møde nr. 559 om Neurodegenerative sygdomme. Skejby Sygehus. 21 Sept. 2006. *Invited speaker*
72. "Modeling late-onset sporadic neurodegenerative disorders". Lessons from parkinsonistic syndromes. Ageing Seminar. Danish Centre for Molecular Gerontology. Aarhus Universitet. 14. Nov. 2006. *Oral presentation*
73. "Cellular modeling of alpha-synuclein aggregation dependent toxicity" The Danish Protein Society, Cellular and Molecular aspects of protein folding and quality control. Tisvilde, Denmark May 2007. *Invited speaker*
- First workshop on Systems BioMedicine of Parkinson's Disease (SBMPD), organized by Drs. Wei-Ping Gai, Flinders University, Australia and Poul Henning Jensen, Aarhus University, Denmark. Lectured on "How do we identify pathological mechanisms underlying cell dysfunctions triggered/sustained by toxic a-synuclein species?" held by the Flinders Neuroscience program at Flinders University, in Adelaide in Australia on July 6. 2007 *Organizer and speaker.*

77. "Pathogenic mechanisms in a-synucleinopathies", satellite meeting in Sydney to the International Brain Research Organisation's (IBRO) World Congress of Neuroscience, in Melbourne, Australia, 8-9 July, 2007 *Invited speaker*.
78. PENS Summer School "Novel molecular strategies to treat neurodegenerative diseases". Lectured on "Mechanisms of degeneration in a-synucleinopathies – a role for p25a?" and "Relevant questions in neurodegeneration". School held at Ofir-Esposende, Portugal. July 2007. *Invited lecturer*.
79. Michael J Fox Foundation Assessment meeting Nov. 28 2007, New York, USA. Presentation of project "Study of the role of phosphorylation at Ser129 in alpha-synuclein induced dopaminergic neurodegeneration in a rodent model of Parkinson's disease". *Invited copresenter*.
80. European Multiple System Atrophy Study Group Napoli, p25a/TPPP in MSA 28-29 marts, 2008. *Invited lecturer*.
81. a-synuclein in Health and Disease, EPFL, Lausanne, Switzerland. Sept 24-26, 2008. "Normal and Pathological Cell Biology of a-synuclein" *Coorganizer and invited speaker*
82. Annual meeting, The PhD research Training Program in Translational medicine. Nov. 27, 2008, Aarhus. "Cell stress in translational medicine" *Invited lecturer*
83. Holme Sogns Torsdagsklub 26 marts, 2009, "Parkinson's sygdom og Alzheimer's sygdom" *invited speaker*
84. "P25a og a-synuclein ved neurodegenerative sygdomme" Statens Serum Institut. 29 april. 2009 *invited speaker*
85. 9<sup>th</sup> Meeting in the Århus Stress group. Stressful impact on brain functions. Århus 10 June 2009, *Coorganizer*
86. Michael J Fox Foundation Assessment meeting 19 June 2009, New York, USA. Presentation of project "Identification of binding proteins for alpha-synuclein oligomers in brain and cells" *Invited presenter*.
87. 18<sup>th</sup> ESN meeting, 4<sup>th</sup> Conference on Advances in molecular Mechanisms of Neurological Disorders, Leipzig, Germany 13 juli 2009. Organizer of workshop "Mechanisms in synucleinopathies" and lectured "Mechanisms in synucleinopathies – intra- and extracellular signaling" Member of int. program committee, *workshop organizer and invited lecturer*
88. Benzon Symposium No. 56 Functional and Pathogenic Protein Aggregation Aug 24-27 Copenhagen 2009. Lectured "Pathways in alpha-synuclein aggregation in living cells" *Coorganizer and invited lecturer*
89. Capital Medical University, Beijing, China, Aug. 29, 2009, Host Professor Xiaomin Wang. "Cellular platforms for screening of neuroprotective drugs against Parkinson's disease related neurodegeneration" *Invited speaker*
90. BINS 4<sup>th</sup> Beijing International Symposium on Neurodegenerative Diseases and Stroke Aug. 29-30 2009 Beijing, China "Update on a-synuclein biology" *Coorganizer and invited speaker*
91. Dansk Selskab for Neurovidenskab jubilæumsmøde/PhD kursus "a-synuclein in Parkinson Disease" København 26-27 november 2009. *Invited speaker*
92. Michael J Fox Foundation Assessment meeting and Alpha-synuclein summit 13-14 January 2010, New York, USA. Presentation of project "Aptamers in synuclein bioimaging" and Summit participant *Invited speaker*
93. Neurasync PhD workshop Athen, Effect of protein misfolding on neuronal cell homeostasis. April 12-16, 2010 *Co-organizer and speaker*
94. Dansk selskab for Neurovidenskab. Årligt møde. Sandbjerg 2-3 maj 2010. "Protein aggregation in neurological diseases". *Invited speaker*
95. Advances in Amyloid Science: From diseases to devices, Ph.D. course and 2nd Scandinavian Amyloid Symposium, 27-29 Sept. 2010 "Sandbjerg, Cytotoxicity of intracellular amyloids or amyloid-like structures" *Invited speaker*
96. Weill Cornell Medical School. Lecture on "Prodegenerative pathways in synucleinopathies" Nov. 9 2010 *Invited seminar*
97. Michael J Fox Foundation a-synuclein Imaging workshop, 10 Nov. 2010. *Invited participant*
98. Workshop "Synuclein in health and disease 2010". San Diego 11-12 November 2010. *Co-organizer and invited speaker*
99. "Transcriptional effects of a-synuclein aggregates" Novartis, Basel, 11 Jan. 2011. *Invited speaker*
- Sino-Danish Neuroscience delegation visiting Chinese Academy of Sciences institutions, Shanghai Institute of Biological Sciences and Institute of Biophysics, Beijing. 23-29 Jan. 2011. *More presentations*.
- 101. Alpha-synuclein aggregation and accumulation. The Danish Weizmann Society, Symposium "Proteins, from creation to destruction" Copenhagen 23-24 May, 2011, *Invited speaker*